Company research
Zura Bio Ltd
CIK 1855644Updated Oct 28, 2026
SecurityZURA · NASDAQ · equity
Name history
JATT Acquisition Corp · through Mar 21, 2023
ZURA price & chart
Loading TradingView…
NASDAQ:ZURA on TradingView ↗About the company
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). A third Phase 2 clinical study in polymyalgia rheumatica (PMR), NEXUS-PMR, is planned to begin by year-end 2026. Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.
In the news
No coverage from other publishers is available.
Seeking Alpha
Stock Picks From Seeking Alpha's March 2026 New Analysts ↗
Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver ↗
SEC disclosures
Zura Bio Ltd files 8-K: Material Event ↗
Recent filings
S-3 filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
S-8 filing
144 filing
Show 5 more recent filings
144 filing
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
144 filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 143,935,000Source | 189,071,000Source | 213,403,000Source | 157,805,000Source | 189,500,000Source | 228,641,000Source | 172,496,000Source | 90,483,000Source | 113,948,000Source | 179,533,000Source | 100,843,000Source | 141,507,839Source |
| Property, Plant and Equipment, NetUSD | 131,000Source | 44,000Source | 149,000Source | 122,000Source | 25,000Source | 125,000Source | 106,000Source | 9,000Source | 126,000Source | 91,000Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 139,017,000Source | 188,221,000Source | 205,134,000Source | 154,490,000Source | — | 225,594,000Source | 170,569,000Source | — | 109,407,000Source | 176,498,000Source | 99,800,000Source | 13,785Source |
| Assets, CurrentUSD | 142,292,000Source | 188,975,000Source | 210,500,000Source | 156,985,000Source | 189,475,000Source | 227,004,000Source | 171,692,000Source | 90,474,000Source | 112,310,000Source | 178,744,000Source | 100,843,000Source | 33,487Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,275,000Source | 754,000Source | 5,366,000Source | 2,495,000Source | — | 1,410,000Source | 1,123,000Source | — | 2,903,000Source | 2,246,000Source | — | — |
| Other Assets, NoncurrentUSD | 1,512,000Source | 52,000Source | 2,754,000Source | 698,000Source | — | 1,512,000Source | 698,000Source | — | 1,512,000Source | 698,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 25,491,000Source | 18,244,000Source | 16,318,000Source | 18,696,000Source | 17,437,000Source | 11,745,000Source | 21,092,000Source | 16,270,000Source | 12,410,000Source | 19,514,000Source | 21,292,000Source | 7,759,733Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 10,000Source | 6,000Source | 6,000Source | 9,000Source | 7,000Source | 4,000Source | 7,000Source | 7,000Source | 4,000Source | — |
| Additional Paid in CapitalUSD | 315,608,000Source | 295,311,000Source | 472,149,000Source | 315,231,000Source | 278,086,000Source | 465,657,000Source | 311,532,000Source | 172,246,000Source | 326,078,000Source | 302,705,000Source | 162,820,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -207,372,000Source | -142,272,000Source | -275,074,000Source | -189,332,000Source | -121,570,000Source | -248,770,000Source | -173,339,000Source | -111,241,000Source | -224,547,000Source | -155,897,000Source | -103,494,000Source | -7,626,591Source |
| Stockholders' Equity Attributable to ParentUSD | 108,243,000Source | 153,046,000Source | — | 125,905,000Source | 156,522,000Source | — | 138,200,000Source | 61,009,000Source | 101,538,000Source | 146,815,000Source | 59,330,000Source | -7,626,246Source |
| Liabilities and EquityUSD | 143,935,000Source | 189,071,000Source | 213,403,000Source | 157,805,000Source | 189,500,000Source | 228,641,000Source | 172,496,000Source | 90,483,000Source | 113,948,000Source | 179,533,000Source | 100,843,000Source | 141,507,839Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 25,491,000Source | 18,244,000Source | 16,318,000Source | 18,696,000Source | 15,073,000Source | 11,745,000Source | 21,092,000Source | 14,674,000Source | 12,410,000Source | 19,514,000Source | 20,302,000Source | 1,828,233Source |
| Accounts Payable, CurrentUSD | 3,275,000Source | 1,014,000Source | 3,283,000Source | 1,205,000Source | 990,000Source | 2,083,000Source | 1,249,000Source | 1,485,000Source | 1,279,000Source | 733,000Source | 2,749,000Source | 282,127Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 1,541,000Source | 1,541,000Source | — | 1,541,000Source | 1,541,000Source | — | 1,541,000Source | 1,541,000Source | — | 1,541,000Source | 1,541,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 1,111,618Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | 8,660,000Source | 16,240,000Source | — | 11,663,000Source | 14,000,000Source | — | 11,663,000Source | 11,663,000Source | — | 11,663,000Source | 18,680,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -24,223,000Source | -17,442,000Source | -68,650,000Source | -52,403,000Source | -60,563,000Source | 3,549,127Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 16,000Source | 9,000Source | 49,000Source | 9,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,008,000Source | 3,644,000Source | 12,332,000Source | 16,798,000Source | 7,469,000Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | — | 212,272Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,923,000Source | -11,063,000Source | -64,815,000Source | -28,076,000Source | -15,054,000Source | -1,071,033Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -13,000Source | -49,000Source | -113,000Source | -5,075,000Source | -8,000,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 13,000Source | 49,000Source | 113,000Source | 75,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 41,000Source | 318,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 135,123,000Source | 5,183,000Source | -2,163,000Source | 109,843,000Source | 121,293,000Source | 355,595Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | -715,438Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 139,017,000Source | 188,221,000Source | 205,134Source | 154,490Source | 225,594,000Source | 170,569,000Source | 109,407,000Source | 176,498,000Source | 99,806,000Source | 13,785Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,379,000Source | 8,646,000Source | 4,457,000Source | 3,732,000Source | 5,008,000Source | 3,644,000Source | 12,332,000Source | 16,798,000Source | 9,655,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -2,000Source | -24,000Source | -84,000Source | 27,000Source | 17,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 2,075,298Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 5,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 7,571,000Source | 13,290,000Source | 8,615,000Source | 9,358,000Source | 10,753,000Source | 8,780,000Source | 33,164,000Source | 30,788,000Source | 18,639,000Source | 2,294,039Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -20,702,000Source | — | — | — | — | — | -52,403,000Source | -60,563,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | -81,000Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | — |
| Investment Income, InterestUSD | — | — | 1,526,000Source | 2,461,000Source | 1,920,000Source | 1,717,000Source | 1,319,000Source | 1,817,000Source | 6,336,000Source | 7,998,000Source | 2,186,000Source | 570Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,040,000Source | -20,702,000Source | -26,304,000Source | -15,993,000Source | -24,223,000Source | -17,442,000Source | -68,650,000Source | -52,403,000Source | -60,360,000Source | 3,549,127Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -20,037,000Source | -22,942,000Source | — | -15,993,000Source | — | -17,442,000Source | -99,353,000Source | -45,386,000Source | -69,243,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 1,479,000Source | -1,383,000Source | 2,936,000Source | 2,069,000Source | 1,276,000Source | 1,812,000Source | 6,596,000Source | 2,786,000Source | — | 6,224,268Source |
| Operating ExpensesUSD | — | — | 19,519,000Source | 19,319,000Source | 29,321,000Source | 18,062,000Source | 25,499,000Source | 19,254,000Source | 75,246,000Source | 55,189,000Source | 62,638,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | -47,000Source | 22,000Source | 1,016,000Source | 352,000Source | -43,000Source | -5,000Source | — | — | 2,075,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 56,683,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 90,000Source | 107,000Source | — | — | — |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Income Taxes Paid, Net | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -19,519,000Source | -19,319,000Source | -29,321,000Source | -18,062,000Source | -25,499,000Source | -19,254,000Source | -75,246,000Source | -55,189,000Source | -62,638,000Source | -2,675,141Source |
| Other Nonoperating Income (Expense)USD | — | — | -47,000Source | 22,000Source | 1,016,000Source | 352,000Source | -43,000Source | -5,000Source | — | — | 2,075,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -18,040,000Source | -20,702,000Source | -26,385,000Source | -15,993,000Source | -24,223,000Source | -17,442,000Source | -68,650,000Source | -52,403,000Source | -60,563,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | -81,000Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,040,000Source | -20,702,000Source | -26,304,000Source | -15,993,000Source | -24,223,000Source | -17,442,000Source | -68,650,000Source | -52,403,000Source | -60,360,000Source | 3,549,127Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.21Source | -0.26Source | -0.21Source | -0.17Source | -0.22Source | -0.19Source | -1.06Source | -0.6Source | -2.09Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.21Source | -0.26Source | -0.21Source | -0.17Source | -0.22Source | -0.19Source | -1.06Source | -0.6Source | -2.09Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 94,564,632Source | 87,335,667Source | 126,803,970Source | 94,289,954Source | 112,222,789Source | 92,964,048Source | 94,160,138Source | 75,070,761Source | 33,064,036Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 94,564,632Source | 87,335,667Source | 126,803,970Source | 94,289,954Source | 112,222,789Source | 92,964,048Source | 94,160,138Source | 75,070,761Source | 33,064,036Source | — |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related CostsUSD | — | — | — | — | — | — | — | — | — | — | 4,000,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -2,000Source | -24,000Source | -84,000Source | 27,000Source | 17,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 2,075,298Source |
| General and Administrative ExpenseUSD | — | — | 7,571,000Source | 13,290,000Source | 8,615,000Source | 9,358,000Source | 10,753,000Source | 8,780,000Source | 33,164,000Source | 30,788,000Source | 18,639,000Source | 2,294,039Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -69,615,000Source | -41,837,000Source | -36,842,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -20,702,000Source | — | — | — | — | — | -52,403,000Source | -60,563,000Source | — |
| Investment Income, InterestUSD | — | — | 1,526,000Source | 2,461,000Source | 1,920,000Source | 1,717,000Source | 1,319,000Source | 1,817,000Source | 6,336,000Source | 7,998,000Source | 2,186,000Source | 570Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -20,037,000Source | -22,942,000Source | — | -15,993,000Source | — | -17,442,000Source | -99,353,000Source | -45,386,000Source | -69,243,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 1,479,000Source | -1,383,000Source | 2,936,000Source | 2,069,000Source | 1,276,000Source | 1,812,000Source | 6,596,000Source | 2,786,000Source | — | 6,224,268Source |
| Operating ExpensesUSD | — | — | 19,519,000Source | 19,319,000Source | 29,321,000Source | 18,062,000Source | 25,499,000Source | 19,254,000Source | 75,246,000Source | 55,189,000Source | 62,638,000Source | — |
| Research and Development ExpenseUSD | — | — | 11,948,000Source | 6,029,000Source | 20,706,000Source | 8,704,000Source | 14,746,000Source | 10,474,000Source | 42,082,000Source | 24,401,000Source | 43,999,000Source | — |
Offerings
Registration 333-299661
Filing attachments
zura-20261027xex991.htm · 8-K · 2026-10-27
Exhibit 99.1 Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target • TibuSURE topline data in systemic sclerosis (SSc) remains on track for H1 2027; enrollment completed with 91 participants randomized, exceeding target • NEXUS-PMR, a Phase 2 study evaluating tibulizumab in polymyalgia rheumatica (PMR), r…
Read attachment ↗tm2628266d1_ex4-3.htm · S-3 · 2026-10-27
Exhibit 4.3 ZURA BIO LIMITED, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms …
Read attachment ↗tm2626146d1_ex99-2.htm · S-8 · 2026-09-30
Exhibit 99.2 ZURA BIO LIMITED 2023 EQUITY INCENTIVE PLAN SHARE OPTION AGREEMENT (ISOs) - U.S. Participant: %%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-% Grant Date: %%OPTION_DATE,'Month DD, YYYY'%-% Type of Option: Incentive Share Option Exercise Price Per Share: %%OPTION_PRICE,'$YYY,YYY,YYY. YY'%-% Total Number of Shares: %%TOTAL_SHARES_GRANTED,’YYY,YYY,YYY’%-% Vesting Commencement Date: %%VEST_BASE_DATE,'Month DD…
Read attachment ↗tm2623351d1_ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 tm2623351d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Overview August 2026 ────────────────────── 2 Forward-Looking Statements Disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potent…
Read attachment ↗zura-20260811xex991.htm · 8-K · 2026-08-11
EX-99.1 2 zura-20260811xex991.htm EX-99.1 Document Exhibit 99.1 Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates • TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 • TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027 • Zura plans to initiate a Phase 2 study for tibulizumab in polym…
Read attachment ↗tm2619483d1_ex99-1.htm · 8-K · 2026-07-01
EX-99.1 2 tm2619483d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Overview July 2026 Nasdaq Ticker: ZURA ─────────────────────── ©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,…
Read attachment ↗